Medicine Service, VA Medical Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Medicine at School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Rheumatology (Oxford). 2018 Mar 1;57(3):451-461. doi: 10.1093/rheumatology/kex232.
The aim was to examine whether allopurinol use is independently associated with a reduction in the risk of incident peripheral arterial disease (PAD) in the US elderly.
We used the 5% random Medicare sample from 2006 to 2012 to examine the association of allopurinol use and duration of use with the risk or hazard of incident PAD in a retrospective cohort study using a new user design. Multivariable Cox regression models adjusted for demographics, co-morbidity, cardiac medications and cardiac conditions. Hazard ratios (HRs) and 95% CIs were calculated.
We identified 26 985 episodes of incident allopurinol use in 25 282 beneficiaries; 3167 allopurinol use episodes (12%) ended in incident PAD. In multivariable-adjusted analyses, allopurinol use was associated with an HR of 0.88 (95% CI: 0.81, 0.95) for incident PAD, as was female gender, HR 0.84 (95% CI: 0.78, 0.90). In a separate multivariable-adjusted model, compared with no allopurinol use, longer durations of allopurinol use were associated with lower HR of PAD: 181 days to 2 years, 0.88 (95% CI: 0.79, 0.97); and >2 years, 0.75 (95% CI: 0.63, 0.89). Other factors significantly associated with a higher HR of PAD were age 75 to < 85 and ⩾85 years, higher Charlson index score and black race. Sensitivity analyses that adjusted for cardiac conditions and medications confirmed these findings, with minimal to no attenuation of HRs.
New allopurinol use was independently associated with a lower risk of PAD in the elderly. Longer allopurinol use durations seemed more protective. Mechanisms of the protective effect need to be investigated in future studies.
本研究旨在探讨别嘌醇的使用是否与美国老年人外周动脉疾病(PAD)发病风险的降低独立相关。
我们使用了 2006 年至 2012 年的 Medicare 5%随机样本,采用新用户设计,在回顾性队列研究中,使用多变量 Cox 回归模型,调整了人口统计学、合并症、心脏药物和心脏状况等因素,研究了别嘌醇的使用及其使用时间与 PAD 发病风险或危险比之间的关系。计算了风险比(HRs)和 95%置信区间(CIs)。
我们在 25282 名受益人中发现了 26985 例别嘌醇使用的新发病例;3167 例别嘌醇使用(12%)最终发生 PAD。在多变量调整分析中,别嘌醇的使用与 PAD 的发病风险呈负相关(HR:0.88,95%CI:0.81,0.95),女性(HR:0.84,95%CI:0.78,0.90)也是如此。在另一个多变量调整模型中,与不使用别嘌醇相比,较长时间的别嘌醇使用与较低的 PAD 风险相关:181 天至 2 年,0.88(95%CI:0.79,0.97);>2 年,0.75(95%CI:0.63,0.89)。与 PAD 发病风险较高显著相关的其他因素包括年龄 75 岁至<85 岁和≥85 岁、更高的 Charlson 指数评分和黑种人。对心脏状况和药物进行调整的敏感性分析证实了这些发现,HR 几乎没有减弱。
新使用别嘌醇与老年人 PAD 风险的降低独立相关。较长时间的别嘌醇使用似乎更具保护作用。需要在未来的研究中调查其保护作用的机制。